YouTube Facebook LinkedIn Google+ Twitter Xingrss  


October 10, 2003

As toxicogenomics becomes more widely adopted and applied at higher throughput, it will have an impact on the continuum of drug discovery and development.

· Perform routine toxicogenomic screening using in vitro and/or in vivo assays

Lead Prioritization

Lead Optimization

Pre-Clinical Safety

PI

P2 Clinical

PIII

· Perform routine toxicogenomic mechanism of toxicity using in vitro and/or in vivo assays

· Discover biomarkers

· Identify blood markers

Back to Microarrays That Make Drugs Safe 







For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.